A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 2, 2005, Pages 138-144

  Moriwaki, Toshikazu ^a   Hyodo, Ichinosuke ^a   Nishina, Tomohiro ^a   Hirao, Ken ^a   Tsuzuki, Takao ^a   Hidaka, Satoshi ^a   Kajiwara, Takeshi ^a   Endo, Shinji ^a   Nasu, Junichirou ^a   Hirasaki, Shoji ^a   Masumoto, Toshikazu ^a   Kurita, Akira ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Clinical trial; Doxifluridine; Gastric cancer; Taxane; Thymidine phosphorylase

Indexed keywords

DOXIFLURIDINE; FULTURON; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS;

EID: 21244500529     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0983-y     Document Type: Article

References (33)

1. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J 4:269-274
2. Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, Cappuzzo F, Stampino CG, Guenzi A (1995) Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 13:2613-2619
3. Bokemeyer C, Hartmann JT, Mayer F, Böhlke I, Kanz L, Von Pawel J, Derigs G, Schröder M (2000) UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors. Oncology 14:63-67
4. Bollag W, Hartmann HR (1980) Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 16:427-432
5. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307-310
6. Cook AF, Holman MJ, Kramer MJ, Trown PW (1979) Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22:1330-1335
7. Di Bartolomeo M, Bajetta E, Somma L, Carnaghi C, Bandieri E, Del Vecchio M, Gallo Stampino C, Buzzoni R (1996) Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 53:54-57
8. Eisenhauer EA (1998) Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 9:1047-1052
9. Glimelius B, Hoffman K, Haglund U, Nyrèn O, Sjödén PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190
10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805
11. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497-503
12. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5- fluorouridine. Gann 71:112-123
13. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
14. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295-301
15. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T (2003) A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64:232-236
16. Löffler TM, Freund W, Lipke J, Hausamen TU (1996) Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 23:32-34
17. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242
18. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279
19. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388
20. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M (1985) Phase II study of 5′-deoxy-5- fluorouridine (5′-DFUR) in patients with malignant cancer - a multi-institutional cooperative study. Gan To Kagaku Ryoho 12:2044-2051
21. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416-419
22. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59
23. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
24. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Parö G (2002) Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418-424
25. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
26. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/ taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019
27. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
28. Shimada Y (1998) Clinical trials for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group. Cancer Chemother Pharmacol [Suppl] 42:S80-S84
29. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203-1209
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
31. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657
32. Wakui A (1988) Phase II study of 5′-deoxy-5-fluororidine in the treatment of gastric cancer. J Int Med Res 16:17B-18B
33. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137